De novo expression of fetal ED-A+ fibronectin and B+ tenascin-C splicing variants in human cardiac allografts: Potential impact for targeted therapy of rejection

Journal of Molecular Histology

Volumn 45, Issue 5, 2014, Pages 519-532

  Franz, Marcus ^a   Matusiak Brückner, Monika ^a   Richter, Petra ^a   Grün, Katja ^a   Ziffels, Barbara ^a   Neri, Dario ^b   Maschek, Hansjörg ^c   Schulz, Uwe ^d   Pfeil, Alexander ^a   Jung, Christian ^a   Figulla, Hans R ^a   Gummert, Jan ^d   Berndt, Alexander ^a   Renner, André ^d  

^a JENA UNIVERSITY HOSPITAL   (Germany)

^b ETH ZURICH   (Switzerland)

^c Institute of Pathology   (Germany)

^d RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

Cardiac rejection; Inflammation; Targeted therapy

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; CD31 ANTIGEN; CD45 ANTIGEN; FIBRONECTIN; TENASCIN; ACTIN; FETOPROTEIN; ISOPROTEIN;

ACUTE GRAFT REJECTION; ALLOGRAFT; ANTIGEN RETRIEVAL; ARTICLE; CARDIAC ALLOGRAFT; CARDIAC GRAFT REJECTION; CARDITIS; CLINICAL ARTICLE; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; FIBROSING ALVEOLITIS; HEART GRAFT; HEART MUSCLE BIOPSY; HEART MUSCLE FIBROSIS; HEART TRANSPLANTATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; ADULT; ALLOTRANSPLANTATION; ALTERNATIVE RNA SPLICING; ANIMAL; BIOSYNTHESIS; COHORT ANALYSIS; CONFOCAL MICROSCOPY; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; GENETICS; GRAFT REJECTION; HEART MUSCLE; MALE; METABOLISM; MIDDLE AGED; MOLECULARLY TARGETED THERAPY; PROCEDURES; RAT; SMOOTH MUSCLE;

CHICKEN ANEMIA VIRUS; RATTUS;

ACTINS; ADULT; ALLOGRAFTS; ALTERNATIVE SPLICING; ANIMALS; ANTIGENS, CD45; COHORT STUDIES; FEMALE; FETAL PROTEINS; FIBRONECTINS; FLUORESCENT ANTIBODY TECHNIQUE; GRAFT REJECTION; HEART TRANSPLANTATION; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICROSCOPY, CONFOCAL; MIDDLE AGED; MOLECULAR TARGETED THERAPY; MUSCLE, SMOOTH; MYOCARDIUM; PROTEIN ISOFORMS; RATS; TENASCIN; TRANSPLANTATION, HOMOLOGOUS;

EID: 84906944811     PISSN: 15672379     EISSN: 15672387     Source Type: Journal    
DOI: 10.1007/s10735-014-9573-4     Document Type: Article

References (50)

1. Armstrong AT, Binkley PF, Baker PB, Myerowitz PD, Leier CV (1998) Quantitative investigation of cardiomyocyte hypertrophy and myocardial fibrosis over 6 years after cardiac transplantation. J Am Coll Cardiol 32:704-710 (Pubitemid 28435257)
2. Baldinger A et al (2011) Comparative analysis of oncofetal fibronectin and tenascin-C expression in right atrial auricular and left ventricular human cardiac tissue from patients with coronary artery disease and aortic valve stenosis. Histochem Cell Biol 135:427-441. doi:10.1007/s00418-011-0809-z
3. Berndt A, Borsi L, Hyckel P, Kosmehl H (2001) Fibrillary co-deposition of laminin-5 and large unspliced tenascin-C in the invasive front of oral squamous cell carcinoma in vivo and in vitro. J Cancer Res Clin Oncol 127:286-292
4. Booth AJ et al (2012) Recipient-derived EDA fibronectin promotes cardiac allograft fibrosis. J Pathol 226:609-618. doi:10.1002/path.3010
5. Borsi L et al (1987) Monoclonal antibodies in the analysis of fibronectin isoforms generated by alternative splicing of mRNA precursors in normal and transformed human cells. J Cell Biol 104:595-600 (Pubitemid 17024714)
6. Borsi L, Balza E, Gaggero B, Allemanni G, Zardi L (1995) The alternative splicing pattern of the tenascin-C pre-mRNA is controlled by the extracellular pH. J Biol Chem 270:6243-6245
7. Cale R, Almeida M, Goncalves P, Rebocho MJ, Raposo L, Teles R, Mendes M (2012) Complications of endomyocardial biopsy after heart transplantation: a lesser evil. Rev Port Cardiol 31:159-162. doi:10.1016/j.repc.2011.12.006
8. Casi G, Neri D (2012) Antibody-drug conjugates: basic concepts, examples and future perspectives. J Controll Release 161:422-428. doi:10.1016/j.jconrel. 2012.01.026
9. Clausell N, Butany J, Molossi S, Lonn E, Gladstone P, Rabinovitch M, Daly PA (1995) Abnormalities in intramyocardial arteries detected in cardiac transplant biopsy specimens and lack of correlation with abnormal intracoronary ultrasound or endothelial dysfunction in large epicardial coronary arteries. J Am Coll Cardiol 26:110-119
10. Coito AJ, Binder J, de Sousa M, Kupiec-Weglinski JW (1994) The expression of extracellular matrix proteins during accelerated rejection of cardiac allografts in sensitized rats. Transplantation 57:599-605 (Pubitemid 24075809)
11. Coito AJ, Brown LF, Peters JH, Kupiec-Weglinski JW, Van de Water L (1997) Expression of fibronectin splicing variants in organ transplantation: a differential pattern between rat cardiac allografts and isografts. Am J Pathol 150:1757-1772 (Pubitemid 27193822)
12. Coito AJ, de Sousa M, Kupiec-Weglinski JW (2000) Fibronectin in immune responses in organ transplant recipients. Dev Immunol 7:239-248
13. Coito AJ, Kato H, Azimi R, Kupiec-Weglinski JW (2001) Chronic allograft rejection versus tolerance: a critical role for EIIIA(+) fibronectin. Transpl Proc 33:526-527 (Pubitemid 32237496)
14. Costanzo MR et al (2010) The international society of heart and lung transplantation guidelines for the care of heart transplant recipients. J Heart Lung Transplant 29:914-956. doi:10.1016/j.healun.2010.05.034
15. Costello JP, Mohanakumar T, Nath DS (2013) Mechanisms of chronic cardiac allograft rejection. Tex Heart Inst J 40:395-399
16. Erba PA et al (2012) Radioimmunotherapy with radretumab in patients with relapsed hematologic malignancies. J Nucl Med 53:922-927. doi:10.2967/jnumed. 111.101006
17. Fiechter M, Frey K, Fugmann T, Kaufmann PA, Neri D (2011) Comparative in vivo analysis of the atherosclerotic plaque targeting properties of eight human monoclonal antibodies. Atherosclerosis 214:325-330. doi:10.1016/j. atherosclerosis.2010.11.027
18. Franz M et al (2007) A quantitative co-localization analysis of large unspliced tenascin-C(L) and laminin-5/gamma2-chain in basement membranes of oral squamous cell carcinoma by confocal laser scanning microscopy. J Oral Pathol Med 36:6-11. doi:10.1111/j.1600-0714.2006.00492.x (Pubitemid 44973981)
19. Franz M et al (2009) Serum levels of large tenascin-C variants, matrix metalloproteinase-9, and tissue inhibitors of matrix metalloproteinases in concentric versus eccentric left ventricular hypertrophy. Eur J Heart Fail 11:1057-1062. doi:10.1093/eurjhf/hfp128
20. Franz M et al (2010a) Changes in extra cellular matrix remodelling and re-expression of fibronectin and tenascin-C splicing variants in human myocardial tissue of the right atrial auricle: implications for a targeted therapy of cardiovascular diseases using human SIP format antibodies. J Mol Histol 41:39-50. doi:10.1007/s10735-010-9260-z
21. Franz M et al (2010b) Extra cellular matrix remodelling after heterotopic rat heart transplantation: gene expression profiling and involvement of ED-A+ fibronectin, alpha-smooth muscle actin and B+ tenascin-C in chronic cardiac allograft rejection. Histochem Cell Biol 134:503-517. doi:10.1007/s00418-010- 0750-6
22. Franz M et al (2011) Expression of extra domain a containing fibronectin in chronic cardiac allograft rejection. J Heart Lung Transplant 30:86-94. doi:10.1016/j.healun.2010.08.015
23. Franz M, Neri D, Berndt A (2012) Chronic cardiac allograft rejection: critical role of ED-A(+) fibronectin and implications for targeted therapy strategies. J Pathol 226:557-561. doi:10.1002/path.3968
24. Franz M et al (2013) Selective imaging of chronic cardiac rejection using a human antibody specific to the alternatively spliced EDA domain of fibronectin. J Heart Lung Transplant 32:641-650. doi:10.1016/j.healun.2013.04. 003
25. Gabler U et al (1996) Matrix remodelling in dilated cardiomyopathy entails the occurrence of oncofetal fibronectin molecular variants. Heart 75:358-362 (Pubitemid 26155567)
26. Glukhova MA, Frid MG, Shekhonin BV, Vasilevskaya TD, Grunwald J, Saginati M, Koteliansky VE (1989) Expression of extra domain a fibronectin sequence in vascular smooth muscle cells is phenotype dependent. J Cell Biol 109:357-366 (Pubitemid 19180142)
27. Gutbrodt KL et al (2013) Antibody-based delivery of interleukin-2 to neovasculature has potent activity against acute myeloid leukemia. Sci Transl Med 5:201ra118. doi:10.1126/scitranslmed.3006221
28. Hamlin SK, Villars PS, Kanusky JT, Shaw AD (2004) Role of diastole in left ventricular function, II: diagnosis and treatment. Am J Crit Care, 13:453-466; quiz 467-458
29. Hemmerle T, Neri D (2013) The antibody-based targeted delivery of interleukin-4 and 12 to the tumor neovasculature eradicates tumors in three mouse models of cancer International journal of cancer Journal international du cancer doi:10.1002/ijc.28359
30. Heuveling DA et al (2013) Phase 0 microdosing PET study using the human mini antibody F16SIP in head and neck cancer patients. J Nucl Med 54:397-401. doi:10.2967/jnumed.112.111310
31. Hiemann NE, Wellnhofer E, Knosalla C, Lehmkuhl HB, Stein J, Hetzer R, Meyer R (2007) Prognostic impact of microvasculopathy on survival after heart transplantation: evidence from 9713 endomyocardial biopsies. Circulation 116:1274-1282. doi:10.1161/CIRCULATIONAHA.106.647149 (Pubitemid 47517539)
32. Imanaka-Yoshida K et al (2001) Tenascin-C modulates adhesion of cardiomyocytes to extracellular matrix during tissue remodeling after myocardial infarction. Lab Invest 81:1015-1024 (Pubitemid 32645977)
33. Imanaka-Yoshida K et al (2002) Tenascin-C is a useful marker for disease activity in myocarditis. J Pathol 197:388-394. doi:10.1002/path.1131 (Pubitemid 34778310)
34. Jones FS, Jones PL (2000) The tenascin family of ECM glycoproteins: structure, function, and regulation during embryonic development and tissue remodeling. Dev Dyn 218:235-259. doi:10.1002/(SICI)1097-0177(200006)218: 2〈235:AID-DVDY2〉3.0.CO;2-G (Pubitemid 30349638)
35. Kobashigawa JA et al (2013) Correlation between myocardial fibrosis and restrictive cardiac physiology in patients undergoing retransplantation. Clin Transplant. doi:10.1111/ctr.12250
36. Minear MA et al (2011) Polymorphic variants in tenascin-C (TNC) are associated with atherosclerosis and coronary artery disease. Hum Genet 129:641-654. doi:10.1007/s00439-011-0959-z
37. Papadia F et al (2013) Isolated limb perfusion with the tumor-targeting human monoclonal antibody-cytokine fusion protein L19-TNF plus melphalan and mild hyperthermia in patients with locally advanced extremity melanoma. J Surg Oncol 107:173-179. doi:10.1002/jso.23168
38. Pasche N, Neri D (2012) Immunocytokines: a novel class of potent armed antibodies. Drug Discov Today 17:583-590. doi:10.1016/j.drudis.2012.01.007
39. Schliemann C, Neri D (2010) Antibody-based vascular tumor targeting Recent results in cancer research. Recent Results Cancer Res 180:201-216. doi:10.1007/978-3-540-78281-0-12
40. Schwager K, Kaspar M, Bootz F, Marcolongo R, Paresce E, Neri D, Trachsel E (2009) Preclinical characterization of DEKAVIL (F8-IL10), a novel clinical-stage immunocytokine which inhibits the progression of collagen-induced arthritis. Arthritis Res Ther 11:R142. doi:10.1186/ar2814
41. Schwarzbauer JE, Sechler JL (1999) Fibronectin fibrillogenesis: a paradigm for extracellular matrix assembly. Curr Opin Cell Biol 11:622-627 (Pubitemid 29460405)
42. Serini G, Bochaton-Piallat ML, Ropraz P, Geinoz A, Borsi L, Zardi L, Gabbiani G (1998) The fibronectin domain ED-A is crucial for myofibroblastic phenotype induction by transforming growth factor-beta1. J Cell Biol 142:873-881 (Pubitemid 28381502)
43. Skalli O, Ropraz P, Trzeciak A, Benzonana G, Gillessen D, Gabbiani G (1986) A monoclonal antibody against alpha-smooth muscle actin: a new probe for smooth muscle differentiation. J Cell Biol 103:2787-2796 (Pubitemid 17008024)
44. Stehlik J et al (2012) The registry of the international society for heart and lung transplantation: 29th official adult heart transplant report. J Heart Lung Transplant 31:1052-1064. doi:10.1016/j.healun.2012.08.002
45. Stewart S et al (2005) Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection. J Heart Lung Transplant 24:1710-1720. doi:10.1016/j.healun.2005.03.019 (Pubitemid 41641841)
46. Suzuki J, Isobe M, Morishita R, Nagai R (2010) Characteristics of chronic rejection in heart transplantation: important elements of pathogenesis and future treatments. Circ J 74:233-239
47. Trachsel E, Kaspar M, Bootz F, Detmar M, Neri D (2007) A human mAb specific to oncofetal fibronectin selectively targets chronic skin inflammation in vivo. J Invest Dermatol 127:881-886. doi:10.1038/sj.jid.5700653 (Pubitemid 46434663)
48. Tsunoda T et al (2003) Involvement of large tenascin-C splice variants in breast cancer progression. Am J Pathol 162:1857-1867. doi:10.1016/S0002- 9440(10)64320-9 (Pubitemid 36613044)
49. Whalley GA, Gamble GD, Doughty RN (2007) The prognostic significance of restrictive diastolic filling associated with heart failure: a meta-analysis. Int J Cardiol 116:70-77. doi:10.1016/j.ijcard.2006.03.032 (Pubitemid 46227608)
50. Zheng W et al (2010) Therapeutic benefits of human mesenchymal stem cells derived from bone marrow after global cerebral ischemia. Brain Res 1310:8-16. doi:10.1016/j.brainres.2009.11.012